Showing results (171-180 of 190) with videos related to
Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2024
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous CancersKara M Schenk, Julie Stein Deutsch, Sunandana Chandra, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2013
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skinF Stephen Hodi, Christopher L Corless, Anita Giobbie-Hurder, et al.Oral Oncology|November 10, 2025
Integrating artificial intelligence-driven digital pathology and genomics to establish patient-derived organoids as new approach methodologies for drug response in head and neck cancerRose Doerfler, Jie Chen, Carl Kim, et al.Nature Communications|July 2, 2026
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 yearsClaus Garbe, Ulrike Keim, Teresa Amaral, et al.Biorxiv : the Preprint Server for Biology|July 16, 2025
Integrating Artificial Intelligence-Driven Digital Pathology and Genomics to Establish Patient-Derived Organoids as a Novel Alternative Model for Drug Response in Head and Neck CancerRose Doerfler, Jie Chen, Carl Kim, et al.Research Square|August 30, 2023
Tumor cell p38 inhibition to overcome immunotherapy resistanceJason J Luke, Rebekah E Dadey, Ryan C Augustin, et al.Lancet (London, England)|April 3, 2022
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trialJason J Luke, Piotr Rutkowski, Paola Queirolo, et al.Cancer Research Communications|November 26, 2025
Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid TumorsBenjamin T Cooper, Wade T Iams, David B Page, et al.Research Square|December 23, 2024
Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancersBrandon M Lehrich, Evan R Delgado, Tyler M Yasaka, et al.Nature Medicine|October 19, 2023
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trialJason J Luke, Manish R Patel, George R Blumenschein, et al.Pageof 19